Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review

Abstract

A systematic review of the published literature (from January 2000 to January 2016) to ascertain the safety of, and patient satisfaction with, the aesthetic use of abobotulinumtoxinA was conducted. In addition to the licensed indications, other special populations were considered for discussion. The potential impact of neutralizing antibodies and systemic toxicity were also addressed. A total of 364 papers were screened and 86 were found to be relevant to the population, intervention(s), and outcomes stipulated in the protocol. The safety and patient satisfaction data from these publications are discussed in this review.Level of Evidence: 2

Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport®/Azzalure®): Primary Results of the APPEAL Noninterventional Study

“…AbobotulinumtoxinA (Dysport ® , Ipsen Biopharm Ltd., Wrexham, UK; Azzalure ® , Galderma Ltd., Lausanne, Switzerland), a preparation of BoNT-A, has been approved for the treatment of moderate-to-severe GL across Europe and the USA since 2009. Although the short- and long-term safety and effectiveness of abobotulinumtoxinA for the treatment of GL is well established [ 5 – 9 ], a thorough investigation of subject satisfaction over repeat treatment cycles has not been performed [ 10 ].…”

A Comparative In Vivo Study on Three Treatment Approaches to Applying Topical Botulinum Toxin A for Crow’s Feet

“…Combinations of BoNTA to correct wrinkles can achieve the same (or better) results compared to an individual treatment approach, potentially in a shorter time frame and convenience to the patient [ 27 , 28 ]. The treatment also results in very high (>90%) patient satisfaction scores [ 28 – 30 ]. Two studies have used a fractional ablative laser to create microscopic columns in the epidermis and dermis that permitted BoNTA molecules to reach the superficial orbicularis oculi in the lower dermis [ 31 , 32 ].…”

Conversion ratio between different botulinum neuroprotein product in neurological practice

“…Нарушение техники введения БТА, неправильно выбранная доза/объем/концентрация препарата БТА может привести к появлению нежелательных явлений. Информация о профиле безопасности при проведении инъекции БТА содержится в инструкции по медицинскому применению каждого препарата [42].…”

“…В систематическом обзоре 2017 г. J. Cohen [42] были проанализированы профиль безопасности и уровень удовлетворенности пациентов при применении диспорта по эстетическим показаниям. Был проведен скрининг 364 публикаций за период с 2000 по 2016 г., из которых для проведения анализа было выбрано 86.…”